Methods and compositions for enhanced nuclease-mediated genome modification and reduced off-target site effects
US-2018362961-A1 · Dec 20, 2018 · US
US2016046972A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016046972-A1 |
| Application number | US-201514742210-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jun 17, 2015 |
| Priority date | Jun 17, 2014 |
| Publication date | Feb 18, 2016 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided are compositions and methods for use in assembling and expressing a plurality of transcription units using, in one aspect, homologous recombination in yeast. Yeast containing the plurality of transcription units, and isolated transcription units, are also provided. Kits for use in making the yeast and the transcript units are further included.
Opening claim text (preview).
What is claimed is: 1 . A method for making recombinant vectors suitable for homologous recombination with each other in yeast comprising: i) providing a first recombinant vector (CDS vector) comprising a protein coding sequence (CDS sequence) wherein the CDS is flanked on its 5′ and 3′ ends by first Type IIS restriction enzyme recognition sites, the CDS vector further comprising a first antibiotic resistance gene; ii) providing a second recombinant vector (PRO vector) comprising a promoter sequence (PRO sequence) wherein the PRO sequence is flanked on its 5′ and 3′ ends by the first Type IIS restriction enzyme recognition sites, the PRO vector further comprising the first antibiotic resistance gene; iii) providing a third recombinant vector (TER vector) comprising a transcription termination sequence (TER sequence) wherein the TER sequence is flanked on its 5′ and 3′ ends by the first restriction Type IIS enzyme recognition sites, the TER vector further comprising the first antibiotic resistance gene; iv) providing a fourth recombinant vector (LVA vector) comprising a first left adapter polynucleotide sequence (LVA sequence) wherein the LVA sequence is flanked on its 5′ and 3′ ends by the first Type IIS restriction enzyme recognition sites, the LVA vector further comprising the first antibiotic resistance gene; v) providing a fifth recombinant vector (RVA vector) comprising a first right adapter polynucleotide sequence (RVA sequence) wherein the RVA sequence is flanked on its 5′ and 3′ ends by the first Type IIS restriction enzyme recognition sites, the RVA vector further comprising the first antibiotic resistance gene; vi) providing a sixth recombinant vector (acceptor vector) comprising a segment, the segment comprising a polynucleotide sequence encoding a detectable marker (detectable marker sequence), wherein the detectable marker sequence is flanked by the first Type IIS restriction enzyme recognition sites, and wherein the segment is flanked by a second Type IIS restriction enzyme recognition sites, wherein the acceptor vector comprises a second antibiotic resistance gene but does not comprise the first antibiotic resistance gene; vii) incubating the CDS vector, the PRO vector, the TER vector, the LVA vector, the RVA vector, and the acceptor vector in a single reaction container with a first Type IIS restriction endonuclease that recognizes the first Type IIS restriction endonuclease recognition site and a DNA ligase enzyme such that ligated vectors are produced, wherein the ligated vectors comprise sequentially the LVA sequence, the PRO sequence, the CDS sequence, the TER sequence, and the RVA sequence (LVA-TU-RVA vectors), wherein the PRO, CDS and TER sequences comprise a transcription unit (TU), and wherein the LVA-TU-RVA vectors comprise the second antibiotic resistance gene, but do not comprise the first antibiotic resistance gene, wherein the LVA-TU-RVA vectors do not comprise the detectable marker sequence, and wherein the ligated vectors do not comprise the first Type IIS restriction site, but do comprise the second Type IIS restriction site; viii) introducing the LVA-TU-RVA vectors from vii) into bacteria and culturing the bacteria with a culture medium comprising an antibiotic to which bacteria comprising the LVA-TU-RVA vectors are resistant via expression of the second antibiotic resistance gene such that clonal colonies of the bacteria comprising the VEGAS vectors are formed, wherein the clonal colonies do not express the detectable marker; and viii) isolating the LVA-TU-RVA vectors from the colonies that do not express the detectable marker to obtain isolated LVA-TU-RVA vectors. 2 . The method of claim 1 , wherein in steps i)-vi): a) the CDS sequence comprises on its 5′ end the sequence: AATG and at its 3′ end the sequence TGAG; and b) the PRO sequence comprises at its 5′ end the sequence: CAGT and at its 3′ end the sequence AATG; and c) the TER sequence comprises at its 5′ end the sequence TGAG and at its 3′ end the sequence TTTT; and d) the LVA sequence comprises at its 5′ end the sequence CCTG and at its 3′ end the sequence CAGT; and; e) the RVA sequence comprises at its 5′ end TTTT and at its 3′ end the sequence AACT; and f) the detectable marker sequence comprises at its 5′ end the sequence CCTG and at its 3′ end the sequence AACT. 3 . The method of claim 1 , wherein the LVA sequence and the RVA sequence on each LVA-TU-RVA vector each comprise between 35-500 base pairs, inclusive, and comprise between 30% and 70% GC base pair composition, and are less than 90% identical in nucleotide sequence to each other, and are less than 90% identical to any contiguous base pair sequence in the genome of a yeast into which the RVA and LVA sequences are intended to be introduced, and wherein the contiguous base pair sequence is the same length as the LVA and the RVA. 4 . The method of claim 1 , wherein the first LVA sequence comprises or consists of the sequence: (VA1*) (SEQ ID NO: 1) CCCCTTAGGTTGCAAATGCTCCGTCGACGGGATCTGTCCTTCTCTGCC GGCGATCGT. 5 . The method of claim 1 , wherein the first RVA sequence comprises or consists of the sequence: (VA2**) (SEQ ID NO: 1) TGACGCTTGGATGCGTGACCCCGTACGTCATGACCCGTCATGGGTATG TAAGCGAAG. 6 . A method for producing a homologously recombined DNA molecule comprising distinct transcription units (TU) of claim 1 , the method comprising: i) providing a plurality of LVA-TU-RVA vectors obtained using the method of claim 1 , wherein each LVA-TU-RVA vector in the plurality comprises a distinct TU that comprises a distinct coding sequence (CDS), and wherein each LVA-TU-RVA vector further comprises a left adapter polynucleotide sequence (LVA sequence) and a right adapter polynucleotide sequence (RVA sequence), wherein only one LVA-TU-RVA vector in the plurality comprises a first LVA sequence (VA1 sequence) that is identical to a first LVA sequence in a yeast VEGAS acceptor vector, and wherein only one LVA-TU-RVA vector in the plurality comprises a first RVA sequence (VA2 sequence) that is identical to a first RVA sequence in the yeast VEGAS acceptor vector; ii) linearizing the plurality of LVA-TU-RVA vectors by digestion with a Type IIS restriction enzyme that recognizes the second Type IIS restriction site of claim 1 to obtain distinct linearized LVA-TU-RVA vector fragments that comprise the distinct TUs; iii) providing a linearized yeast VEGAS acceptor vector that comprises at one end the VA1 sequence and at the other end the VA2 sequence, the linearized yeast VEGAS acceptor vector further comprising a sequence encoding selectable marker functional in bacteria, a selectable marker functional in yeast, a yeast centromere (CEN) sequence, and a yeast autonomously replicating sequences (ARS); iv) introducing into the yeast the linearized yeast VEGAS acceptor vector and the distinct linearized LVA-TU-RVA vector fragments that comprise the distinct TUs; v) allowing homologous recombination in the yeast so that the only one LVA-TU-RVA vector segment comprising the VA1 sequence and the only one LVA-TU-RVA vector segment comprising the VA2 sequence ar
using homologous recombination · CPC title
General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host · CPC title
General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease · CPC title
for yeasts · CPC title
in yeast · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.